Top Movers | BBIO Skyrockets 70% on Drug Results! BKI-ICE Merger Is More Possible on Unit Sale
@WallStreet_Tiger:
1. $BridgeBio Pharma, Inc.(BBIO)$ +75.85%: analysts are positive on upbeat results from heart drug trial BridgeBio, a pharmaceutical company, experienced a significant surge in its stock price, rising as much as 70% in response to positive results from a late-stage trial of its cardiovascular disease treatment. According to a Mizuho analyst, the trial results surpassed even the most optimistic scenarios anticipated by the market.Mizuho's Salim Syed, who has a "buy" rating on the stock and a price target of $29, praised the trial data, describing it as "super clean and very consistent across measures." Based on the positive trial data, he believes that the stock has the potential to reach levels above $40.Additionally, Raymond James analy